stockrowVir Biotechnology, Inc.
VIRVir Biotechnology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $68.6 million, down 7.61% from fiscal 2024.
- Revenue
- −178.3%
- EPS
- +51.4%
- Free cash flow
- +36.8%
Quarter to September 2026, against a year earlier
Follow VIR
Alert me
Vir Biotechnology, Inc. (VIR) Operating cash flow
Vir Biotechnology, Inc.'s operating cash flow for fiscal 2025 was −$391.8M, compared with −$446.4M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$141.0M. Over the past ten years it has ranged from −$778.8M (fiscal 2023) to $1.7B (fiscal 2022); the current reading is higher than 33% of that period. Vir Biotechnology, Inc. ranks 493rd of 603 Biotechnology companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | −$391.8M | — |
| FY2024 | −$446.4M | — |
| FY2023 | −$778.8M | — |
| FY2022 | $1.7B | — |
| FY2021 | −$47.6M | — |
| FY2020 | −$190.9M | — |
| FY2019 | −$129.6M | — |
| FY2018 | −$94.1M | — |
| FY2017 | −$66.4M | — |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Sep 2026 | −$106.1M | — |
| Jun 2026 | $123.3M | — |
| Mar 2026 | −$132.4M | — |
| Dec 2025 | −$25.9M | — |
| 30 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| ZYME Zymeworks Inc. compare | −$112.0M |
| TRAX First Tracks Biotherapeutics, Inc. compare | −$112.2M |
| VIR Vir Biotechnology, Inc. | −$141.0M |
| NAMS NewAmsterdam Pharma Company N.V. compare | −$150.5M |
| IMNM Immunome, Inc. compare | −$229.0M |
| REPL Replimune Group, Inc. compare | −$245.5M |
| RXRX Recursion Pharmaceuticals, Inc. compare | −$310.5M |
| BHVN Biohaven Ltd. compare | −$472.5M |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | −$508.0M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on VIR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement